LAIR1 (leukocyte-associated immunoglobulin-like receptor 1) is an inhibitory immune checkpoint receptor widely expressed on hematopoietic cells, particularly immune cells including NK cells, T cells, B cells, and myeloid cells 1. The receptor functions as a pattern recognition receptor that binds collagen and collagen domain-containing proteins through a common structural motif 2. Upon activation, LAIR1 recruits phosphatases PTPN6 (SHP-1) and PTPN11 through its immunoreceptor tyrosine-based inhibitory motifs, delivering suppressive signals that regulate immune cell homeostasis and function 34. In the tumor microenvironment, LAIR1 promotes immunosuppression by inducing CD8+ T cell exhaustion through SHP-1 signaling and supporting M2-like tumor-associated macrophage phenotypes 35. Elevated collagen-LAIR1 interactions correlate with resistance to PD-1/PD-L1 checkpoint blockade therapy and poor clinical outcomes in cancer patients 3. LAIR1 also regulates myeloid cell survival, proliferation, and differentiation, with deficiency leading to altered monocyte frequencies and macrophage heterogeneity 4. The receptor's dual role in maintaining immune homeostasis while potentially promoting tumor immune escape makes it an attractive therapeutic target, with multiple clinical trials investigating LAIR1 blockade for cancer treatment 25.